Invivyd, Inc. (NASDAQ:IVVD) Short Interest Up 24.4% in December

Invivyd, Inc. (NASDAQ:IVVD) saw a large increase in short interest in the month of December. As of December 31st, there was short interest totaling 35,613,115 shares, an increase of 24.4% from the December 15th total of 28,634,579 shares. Based on an average daily volume of 5,706,265 shares, the short-interest ratio is presently 6.2 days. Approximately 20.5% of the company’s shares are sold short. Approximately 20.5% of the company’s shares are sold short. Based on an average daily volume of 5,706,265 shares, the short-interest ratio is presently 6.2 days.

Invivyd Stock Up 0.4%

Shares of IVVD stock traded up $0.01 during mid-day trading on Monday, reaching $2.45. 1,802,177 shares of the company’s stock traded hands, compared to its average volume of 3,340,812. The company’s 50-day moving average price is $2.41 and its 200-day moving average price is $1.60. The company has a market cap of $571.14 million, a P/E ratio of -5.21 and a beta of 0.61. Invivyd has a 12 month low of $0.35 and a 12 month high of $3.07.

Invivyd (NASDAQ:IVVD) last issued its quarterly earnings results on Thursday, November 6th. The company reported ($0.06) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.05) by ($0.01). Invivyd had a negative return on equity of 92.97% and a negative net margin of 119.63%.The business had revenue of $13.13 million during the quarter, compared to the consensus estimate of $12.00 million. Equities analysts predict that Invivyd will post -1.64 earnings per share for the current year.

Insider Buying and Selling

In other Invivyd news, Director Kevin F. Mclaughlin purchased 50,000 shares of the stock in a transaction on Wednesday, November 19th. The stock was acquired at an average price of $2.50 per share, with a total value of $125,000.00. Following the transaction, the director directly owned 50,000 shares of the company’s stock, valued at approximately $125,000. This trade represents a ∞ increase in their position. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. 25.40% of the stock is owned by insiders.

Institutional Trading of Invivyd

A number of hedge funds have recently made changes to their positions in IVVD. Catalyst Funds Management Pty Ltd bought a new position in Invivyd during the 2nd quarter valued at approximately $27,000. Vanguard Personalized Indexing Management LLC boosted its holdings in Invivyd by 238.6% in the second quarter. Vanguard Personalized Indexing Management LLC now owns 39,941 shares of the company’s stock worth $29,000 after acquiring an additional 28,146 shares in the last quarter. Bank of America Corp DE grew its stake in shares of Invivyd by 330.5% in the third quarter. Bank of America Corp DE now owns 49,252 shares of the company’s stock worth $54,000 after acquiring an additional 37,811 shares during the last quarter. SG Americas Securities LLC bought a new position in shares of Invivyd during the fourth quarter valued at $60,000. Finally, Invesco Ltd. increased its holdings in shares of Invivyd by 190.6% during the first quarter. Invesco Ltd. now owns 108,999 shares of the company’s stock valued at $66,000 after acquiring an additional 71,485 shares in the last quarter. 70.36% of the stock is owned by institutional investors.

Analysts Set New Price Targets

A number of equities analysts recently commented on IVVD shares. HC Wainwright upped their target price on Invivyd from $5.00 to $10.00 and gave the company a “buy” rating in a report on Friday, October 31st. D Boral Capital downgraded shares of Invivyd from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, November 25th. Zacks Research raised shares of Invivyd from a “strong sell” rating to a “hold” rating in a research report on Thursday, November 13th. D. Boral Capital reaffirmed a “hold” rating on shares of Invivyd in a research note on Tuesday, November 25th. Finally, BTIG Research began coverage on shares of Invivyd in a research report on Monday, December 22nd. They set a “buy” rating and a $10.00 price target on the stock. Three research analysts have rated the stock with a Buy rating, three have issued a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat.com, the company currently has an average rating of “Hold” and an average target price of $8.00.

About Invivyd

Invivyd, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of antibody-based solutions for infectious diseases in the United States. The company developed INVYMAB, a platform that combines viral surveillance and predictive modeling with advanced antibody engineering. Its pipeline includes PEMGRADA (pemivibart) injection, a half-life extended investigational monoclonal antibody (mAb) for the prevention of COVID-19 in adults and adolescents; VYD2311, an mAb candidate which is in preclinical studies for the prevention or treatment for COVID-19; and adintrvimab, that is in phase 3 clinical trials for the prevention or treatment of COVID-19.